Survival of patients with lung cancer treated with vincristine and actinomycin D. An unsuccessful trial

Twenty‐five patients with lung cancer were treated with actinomycin‐D and vincristine (V‐D) with only one objective response (IMD). The survival of these patients was compared retrospectively to a group of 49 consecutive patients treated with radiotherapy only during the same time period. Median survival times for the V‐D group and radiotherapy controls were 6.5 and 7.5 months, respectively. It is concluded that V‐D did not increase survival in patients with lung cancer and should be dropped from the chemotherapeutic armamentarium in lung cancer.